Stay updated on Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.

Latest updates to the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page
- CheckyesterdayChange DetectedFooter revision badge updated from Revision: v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check8 days agoChange DetectedAdded Local Institution - 315 and related topics (Schizophrenia; MedlinePlus Genetics). Removed contact details for UMHAT 'Dr Georgi Stranski' and Maya Stoimenova-Popova at Site 315.SummaryDifference0.3%

- Check15 days agoChange Detected- Added Revision: v3.4.3 and removed references to Schizophrenia, related topics (MedlinePlus Genetics), and Revision: v3.4.2.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded updated contact phone number (314-498-9799) and collaborator information (Karuna Therapeutics, Inc., a Bristol Myers Squibb company).SummaryDifference0.1%

- Check43 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous notices including the funding lapse notice and the earlier Revision: v3.4.1.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 with no visible changes to the study details; to avoid alerts for small changes, set an alert condition below.SummaryDifference0.0%

Stay in the know with updates to Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.